Approved Lurbinectedin Combination
Lurbinectedin ( Zepzelca) is FDA-approved for metastatic small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy. The standard regimen is 150 mg/m² intravenous infusion over 60 minutes on day 1 of a 21-day cycle, combined with atropine 0.25 mg IV (or subcutaneous) 30 minutes before each lurbinectedin dose to prevent nausea and vomiting.[1][2]
Common Chemotherapy Pairings in Trials
Clinical studies and ongoing trials pair lurbinectedin with chemotherapy for broader SCLC treatment or other solid tumors:
- Lurbinectedin + irinotecan: Tested in relapsed SCLC (IMforte trial), showing improved response rates.[3]
- Lurbinectedin + doxorubicin: Evaluated for extensive-stage SCLC in frontline settings.[4]
- Lurbinectedin + atezolizumab: Phase III trial (IMforte) for relapsed SCLC after immunotherapy.[3]
Investigational Combinations in Clinical Trials
Lurbinectedin appears in over 50 active trials on ClinicalTrials.gov, often with immunotherapy or targeted agents:
| Combination | Tumor Type | Phase | Notes |
|-------------|------------|-------|-------|
| Lurbinectedin + pembrolizumab | SCLC, thymic carcinoma | II/III | Enhances immune checkpoint response.[5] |
| Lurbinectedin + irinotecan + atezolizumab | Extensive-stage SCLC | III | First-line after chemo-immunotherapy failure.[6] |
| Lurbinectedin + olaparib | SCLC, ovarian cancer | II | PARP inhibitor synergy for BRCA-mutated cases.[7] |
| Lurbinectedin + binimetinib | Uterine leiomyosarcoma | II | MEK inhibitor for soft tissue sarcomas.[8] |
These target platinum-resistant or relapsed disease, with response rates up to 35-50% in sensitive SCLC subsets.[3][4]
Why These Combinations?
Lurbinectedin traps DNA-topoisomerase complexes, synergizing with chemotherapies that induce DNA damage (e.g., irinotecan, doxorubicin) or immunotherapies that boost T-cell activity. Atropine is routine to manage cholinergic side effects like diarrhea.[2]
Sources
[1]: FDA Label - Zepzelca (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf)
[2]: NCCN Guidelines - SCLC Version 3.2024 (https://www.nccn.org/guidelines)
[3]: Trigo et al., Lancet Oncol 2021 (IMforte trial)
[4]: ClinicalTrials.gov NCT02454972
[5]: ClinicalTrials.gov NCT03953235
[6]: ClinicalTrials.gov NCT04796054
[7]: ClinicalTrials.gov NCT03367423
[8]: ClinicalTrials.gov NCT04805570